CWA Asset Management Group LLC Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

CWA Asset Management Group LLC raised its position in Eli Lilly and Company (NYSE:LLY – Get Rating) by 28.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,446 shares of the company’s stock after acquiring an additional 323 shares during the quarter. CWA Asset Management Group LLC’s holdings in Eli Lilly and were worth $529,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Benjamin Edwards Inc. lifted its holdings in Eli Lilly and by 0.7% during the 3rd quarter. Benjamin Edwards Inc. now owns 3,836 shares of the company’s stock valued at $1,240,000 after buying an additional 28 shares in the last quarter. Moloney Securities Asset Management LLC lifted its holdings in Eli Lilly and by 0.6% during the 3rd quarter. Moloney Securities Asset Management LLC now owns 5,000 shares of the company’s stock valued at $1,617,000 after buying an additional 28 shares in the last quarter. Auxano Advisors LLC lifted its holdings in Eli Lilly and by 2.1% during the 3rd quarter. Auxano Advisors LLC now owns 1,385 shares of the company’s stock valued at $448,000 after buying an additional 28 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its holdings in Eli Lilly and by 1.7% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 1,774 shares of the company’s stock valued at $574,000 after buying an additional 29 shares in the last quarter. Finally, Avidian Wealth Solutions LLC lifted its holdings in Eli Lilly and by 0.4% during the 3rd quarter. Avidian Wealth Solutions LLC now owns 7,354 shares of the company’s stock valued at $2,378,000 after buying an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 82.13% of the company’s stock.

Eli Lilly and Stock Down 0.1 %

LLY stock opened at $329.18 on Friday. The firm has a 50 day moving average of $335.87 and a 200 day moving average of $341.41. The stock has a market capitalization of $312.82 billion, a PE ratio of 47.71, a price-to-earnings-growth ratio of 1.88 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.05 and a debt-to-equity ratio of 1.37. Eli Lilly and Company has a 52 week low of $276.83 and a 52 week high of $384.44.

Eli Lilly and (NYSE:LLY – Get Rating) last released its earnings results on Thursday, February 2nd. The company reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.26. The company had revenue of $7.30 billion during the quarter, compared to analysts’ expectations of $7.39 billion. Eli Lilly and had a net margin of 21.88% and a return on equity of 73.61%. Eli Lilly and’s revenue for the quarter was down 8.7% on a year-over-year basis. During the same period last year, the business earned $2.49 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 8.49 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Anne E. White sold 2,500 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 13th. The shares were sold at an average price of $346.47, for a total value of $866,175.00. Following the completion of the sale, the executive vice president now directly owns 57,926 shares in the company, valued at approximately $20,069,621.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.12% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on LLY. StockNews.com began coverage on shares of Eli Lilly and in a report on Thursday. They set a “buy” rating for the company. Credit Suisse Group raised their target price on shares of Eli Lilly and from $395.00 to $400.00 and gave the company an “outperform” rating in a research report on Tuesday, December 6th. Societe Generale downgraded shares of Eli Lilly and from a “hold” rating to a “sell” rating and set a $278.00 target price on the stock. in a research report on Wednesday, February 15th. Cowen raised their target price on shares of Eli Lilly and from $390.00 to $430.00 in a research report on Monday, December 5th. Finally, UBS Group cut their target price on shares of Eli Lilly and from $428.00 to $420.00 and set a “buy” rating on the stock in a research report on Thursday, December 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $382.05.

About Eli Lilly and

(Get Rating)

Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.